lansoprazole has been researched along with Obesity in 6 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed 306 children between 6 and 17 years of age with poorly controlled asthma enrolled in a 6-month trial assessing lansoprazole for asthma control." | 5.17 | Obesity in children with poorly controlled asthma: Sex differences. ( Dixon, AE; Holbrook, JT; Irvin, CG; Lang, JE; Lima, JJ; Shade, D; Teague, WG; Wei, CY; Wise, RA, 2013) |
| "Lansoprazole was administered for 8 weeks and HRQOL assessed using the SF-8 and a newly developed questionnaire for RE-specific HRQOL (RESQ) at baseline and after 4 and 8 weeks of treatment." | 2.73 | The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study. ( Ashida, K; Hongo, M; Kinoshita, Y; Miwa, H, 2008) |
| "Global rates of obesity and type 2 diabetes mellitus (T2DM) are increasing globally concomitant with a rising prevalence of sleep deprivation and sleep disorders." | 2.72 | The links between sleep duration, obesity and type 2 diabetes mellitus. ( Antza, C; Kostopoulos, G; Mostafa, S; Nirantharakumar, K; Tahrani, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Antza, C | 1 |
| Kostopoulos, G | 1 |
| Mostafa, S | 1 |
| Nirantharakumar, K | 1 |
| Tahrani, A | 1 |
| Benchamana, A | 1 |
| Mori, H | 1 |
| MacDougald, OA | 1 |
| Soodvilai, S | 1 |
| Hao, S | 1 |
| Sun, J | 1 |
| Tian, X | 1 |
| Sun, X | 1 |
| Zhang, Z | 1 |
| Gao, Y | 1 |
| Lin, WS | 1 |
| Huang, CW | 1 |
| Song, YS | 1 |
| Yen, JH | 1 |
| Kuo, PC | 1 |
| Yeh, SR | 1 |
| Lin, HY | 1 |
| Fu, TF | 1 |
| Wu, MS | 1 |
| Wang, HD | 1 |
| Wang, PY | 1 |
| Hongo, M | 1 |
| Kinoshita, Y | 1 |
| Miwa, H | 1 |
| Ashida, K | 1 |
| Lang, JE | 1 |
| Holbrook, JT | 1 |
| Wise, RA | 1 |
| Dixon, AE | 1 |
| Teague, WG | 1 |
| Wei, CY | 1 |
| Irvin, CG | 1 |
| Shade, D | 1 |
| Lima, JJ | 1 |
1 review available for lansoprazole and Obesity
| Article | Year |
|---|---|
The links between sleep duration, obesity and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Lansoprazole; Life Style; Obesity; Risk Facto | 2021 |
2 trials available for lansoprazole and Obesity
| Article | Year |
|---|---|
The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Anti-Ulcer Agents; Esophagitis, P | 2008 |
Obesity in children with poorly controlled asthma: Sex differences.
Topics: Adolescent; Asthma; Body Mass Index; Child; Cohort Studies; Female; Forced Expiratory Volume; Humans | 2013 |
3 other studies available for lansoprazole and Obesity
| Article | Year |
|---|---|
Regulation of adipocyte differentiation and metabolism by lansoprazole.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; CCAAT-Enhancer-Binding Protein-alpha; Cell Differen | 2019 |
Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.
Topics: Adult; Animals; Area Under Curve; Blood Glucose; C-Peptide; Diet; Drug Synergism; Drug Therapy, Comb | 2014 |
Reduced Gut Acidity Induces an Obese-Like Phenotype in Drosophila melanogaster and in Mice.
Topics: Acetazolamide; Acid-Base Equilibrium; Animals; Carbonic Anhydrase Inhibitors; Drosophila melanogaste | 2015 |